Given the challenges associated with the classification of high-grade NENs (G3 NETs/NEC), the integration of additional molecular biomarkers, such as Rb, p53 ATRX, DAXX, and menin, has been recently proposed as a means of generating a more accurate diagnosis [3]. The gene discussed is ATRX; the disease is neuroendocrine carcinoma.